Black Diamond Therapeutics Inc (BDTX) FinancialsBDTXFinancialBlack Diamond Therapeutics Inc

Evaluating the bottom line, Black Diamond Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -37.21%, provide a clear picture of how effectively BDTX converts its operational activities into shareholder value.

In the context of the broader market, BDTX competes directly with industry leaders such as MXCT and PMN. With a market capitalization of $116.06M, it holds a significant position in the sector. When comparing efficiency, BDTX's gross margin of N/A stands against MXCT's 63.86% and PMN's N/A. Such benchmarking helps identify whether Black Diamond Therapeutics Inc is trading at a premium or discount relative to its financial performance.

The company reported a total revenue of $70 million in Q1 2025, with a gross margin of 100% during that period, showcasing strong potential for profitability. However, it has also faced significant net losses, with a net income of -$15.9 million in Q4 2024.